Karyopharm Therapeutics (KPTI) Financial Statements

3 Followers

Karyopharm Therapeutics Financial Overview

Karyopharm Therapeutics's market cap is currently CHF12.37M. The company's EPS TTM is CHF-22.32; its P/E ratio is -0.03; Karyopharm Therapeutics is scheduled to report earnings on October 29, 2026, and the estimated EPS forecast is CHF―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	$ 146.07M	$ 145.24M	$ 146.03M	$ 157.07M	$ 209.82M
Gross Profit	$ 140.12M	$ 139.23M	$ 141.09M	$ 151.86M	$ 206.42M
Operating Income	$ -90.71M	$ -119.44M	$ -129.54M	$ -142.20M	$ -98.27M
EBITDA	$ -149.85M	$ -38.60M	$ -118.42M	$ -139.31M	$ -96.98M
Net Income	$ -196.04M	$ -76.42M	$ -143.10M	$ -165.29M	$ -124.09M
Balance Sheet
Cash & Short-Term Investments	$ 63.74M	$ 108.71M	$ 191.44M	$ 277.97M	$ 228.62M
Total Assets	$ 108.42M	$ 164.42M	$ 240.44M	$ 358.17M	$ 305.31M
Total Debt	$ 233.61M	$ 194.52M	$ 177.02M	$ 179.07M	$ 180.58M
Net Debt	$ 173.07M	$ 132.05M	$ 124.78M	$ 43.89M	$ -9.88M
Total Liabilities	$ 401.34M	$ 350.44M	$ 376.64M	$ 374.83M	$ 384.98M
Stockholders' Equity	$ -292.93M	$ -186.02M	$ -136.21M	$ -16.66M	$ -79.67M
Cash Flow
Free Cash Flow	$ -75.37M	$ -127.63M	$ -92.72M	$ -149.67M	$ -112.83M
Operating Cash Flow	$ -75.37M	$ -127.49M	$ -92.72M	$ -149.55M	$ -107.12M
Investing Cash Flow	$ 43.38M	$ 95.47M	$ 7.94M	$ -104.26M	$ 141.84M
Financing Cash Flow	$ 30.05M	$ 41.65M	$ 1.12M	$ 193.74M	$ 73.65M

Currency in USD

Karyopharm Therapeutics Earnings and Revenue History

Income Statement >

Karyopharm Therapeutics Debt to Assets

Balance Sheet >

Karyopharm Therapeutics Cash Flow

Cash Flow >

Karyopharm Therapeutics Forecast EPS vs Actual EPS

Earnings >